Drug intelligence / Profile preview

albiglutide

Development stage: Phase 4
Lead developer: GSK
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Albiglutide is a recombinant fusion protein and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It consists of a dipeptidyl peptidase-4-resistant GLP-1 dimer fused to human albumin, which prolongs its half-life and allows for once-weekly subcutaneous administration. Albiglutide increases glucose-dependent insulin secretion and slows gastric emptying by activating the GLP-1 receptor. It was developed by GlaxoSmithKline and marketed under the brand names Tanzeum (US) and Eperzan (EU). The drug has been discontinued[2][3][5][6].

Brand names: TanzeumEperzan
Other names: albiglutide

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on albiglutide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on albiglutide.

Explore the full profile